Latest News & Features
Refine Search
Americas
The US Food and Drug Administration has proposed using four-letter suffixes to name biosimilar drugs. 1 September 2015
Americas
US pharmaceutical company Eli Lilly has thwarted attempts by its competitors to market a generic version of its Alimta (pemetrexed) drug. 27 August 2015
Big Pharma
The competence in various areas of the new Unified Patent Court is a matter of conjecture, as Paul England and Christof Höhne of law firm Taylor Wessing report. 27 August 2015
Americas
Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval. 26 August 2015
Americas
Hedge fund manager Kyle Bass has been dealt a blow after failing to invalidate two patents owned by biotechnology company Acorda Therapeutics. 25 August 2015
Americas
Sandoz, Allergan and Accord Healthcare have demonstrated “clear and convincing” evidence that a patent owned by Millennium Pharmaceuticals and used in its Velcade cancer treatment drug is invalid, according to a US court ruling. 24 August 2015
Asia
The Indian government has rejected a request by local company Lee Pharma to issue a compulsory licence for AstraZeneca’s diabetes drug Onglyza. 24 August 2015
Americas
Biopharmaceutical company Omeros has said that it plans to sue Par Pharmaceutical over its attempt to market a generic version of Omeros's eye treatment drug Omidria. 20 August 2015
Americas
A recent decision in Canada means defendants in patent infringement cases can raise the non-infringing alternative defence in response to damages claims. Mark Biernacki and Cameron Weir of Smart & Biggar/Fetherstonhaugh considers its potential impact on litigation between drugs companies. 20 August 2015
Americas
Sequenom has requested an en banc review of the US Court of Appeals for the Federal Circuit’s decision to invalidate one of its patents in its dispute with Ariosa Diagnostics, arguing that the decision creates an “existential threat” to patent protection. 19 August 2015